Clinical trials: Central Line Complication
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-22 (NCT03123055)
- Testing
- B-701, Pembrolizumab
- Where
- 52 sites in United States, Belgium and 15 more
- Volunteers
- 28 people
- Sponsor
- Rainier Therapeutics
Cancer, Ovarian Cancer
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
- Conditions
- Cancer, Ovarian Cancer, Solid Tumor
- Trial name
- NCT00753740
- Testing
- IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose)
- Where
- 7 sites in United States
- Sponsor
- NewLink Genetics Corporation
Catheter Related Infections, Short Bowel Syndrome
Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome
This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome.
- Trial name
- NCT01263574
- Testing
- 70% ethanol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
End-Stage Kidney Disease, Hemodialysis Complication
The Arteriovenous Vascular (AV) ACCESS Trial
This study is to prospectively compare the effectiveness and safety of the two types of arteriovenous access placement (fistula or graft) in older adults with end stage kidney disease and multiple chronic conditions
- Trial name
- NCT04646226
- Testing
- AV graft, surgical intervention for creation of a fistula
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Wake Forest University Health Sciences
Catheter Related Complication
Verification of the Correct Insertion of a Central Venous Catheter
The investigators propose a prospective diagnostic validity study in which the correct location of the central venous catheter will be verified by ultrasound and then verified by radiography in the same patient, without modifying…
- Trial name
- NCT06109584
- Testing
- Insertion of central venous catheter
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Consorci Sanitari de Terrassa
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer, HGSOC
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer.
- Conditions
- Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Trial name
- OVACT (NCT07665515)
- Testing
- CryptiVax-1001
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Epitopea Ltd
Cervical Cancer
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT05179239
- Testing
- SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with…
- Trial name
- NICHOL (NCT06594679)
- Testing
- Niraparib Tosylate Monohydrate
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano